- Home
- ZVSA vs INM Comparison
ZVSA vs INM Comparison
Compare ZVSA & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- INM
- Stock Information
- Founded
- ZVSA 2014
- INM 1981
- Country
- ZVSA United States
- INM Canada
- Employees
- ZVSA N/A
- INM N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- INM Health Care
- Exchange
- ZVSA Nasdaq
- INM Nasdaq
- Market Cap
- ZVSA 3.0M
- INM 3.2M
- IPO Year
- ZVSA N/A
- INM N/A
- Fundamental
- Price
- ZVSA $0.67
- INM $2.90
- Analyst Decision
- ZVSA
- INM
- Analyst Count
- ZVSA 0
- INM 0
- Target Price
- ZVSA N/A
- INM N/A
- AVG Volume (30 Days)
- ZVSA 1.3M
- INM 5.7M
- Earning Date
- ZVSA 08-08-2025
- INM 05-12-2025
- Dividend Yield
- ZVSA N/A
- INM N/A
- EPS Growth
- ZVSA N/A
- INM N/A
- EPS
- ZVSA N/A
- INM N/A
- Revenue
- ZVSA N/A
- INM $4,920,990.00
- Revenue This Year
- ZVSA N/A
- INM N/A
- Revenue Next Year
- ZVSA N/A
- INM N/A
- P/E Ratio
- ZVSA N/A
- INM N/A
- Revenue Growth
- ZVSA N/A
- INM N/A
- 52 Week Low
- ZVSA $0.47
- INM $1.72
- 52 Week High
- ZVSA $6.30
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- ZVSA 53.47
- INM 50.30
- Support Level
- ZVSA $0.63
- INM $2.93
- Resistance Level
- ZVSA $0.71
- INM $5.50
- Average True Range (ATR)
- ZVSA 0.06
- INM 0.36
- MACD
- ZVSA 0.00
- INM 0.01
- Stochastic Oscillator
- ZVSA 66.39
- INM 22.22
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.